News

Pharmapack announce key themes for Pharmapack Europe 2020

Connectivity, customization and sustainability are driving pharmaceutical packaging and drug delivery innovation at Pharmapack Europe (#pharmapackeu), which opens in February 2020. The event is the leading exhibition dedicated to pharmaceutical packaging and drug delivery devices, with major industry players...

Bora appoints President to strengthen North American team

Bora, a contract development and manufacturing organization (CDMO) which specializes in modified release and solvent production, has announced the appointment of Samuel Ricchezza as President of North America Operations. Bringing over 25 years’ CDMO experience to the team, Ricchezza is...

Neuraxpharm expands Southern Europe operations with Portugal unit

European speciality pharmaceutical company Neuraxpharm Group has announced the launch of Neuraxpharm Portugal as part of an expansion of its operations in Southern Europe. Neuraxpharm Portugal will be based in Lisbon and be part of the Southern European Region, which...

Big pharma agrees to drastically cut prices of blockbuster drugs in China

China’s National Healthcare Security Administration (NHSA) has announced it has agreed an average 61% cut in prices of 70 top-selling drugs with large pharma manufacturers in exchange for inclusion on a state-run insurance scheme list. According to the South China...

FDA approves Aleors Diclofenac sodium topical solution

The US Food and Drug Administration (FDA) has granted tentative approval for Aleor Dermaceuticals’ Diclofenac sodium topical solution USP, 2% w / w to treat the pain of osteoarthritis of the knees. Aleor is a 60:40 joint venture (JV) between...

High Purity New England Launches Single Use Mixing System

High Purity New England, a leading supplier of biotech equipment and process systems for the Biotech industry, has launched ClearMixx, an innovative single use mixing system. The latest addition to the growing High Purity New England product range, ClearMixx utilizes...

ImmuPharma signs agreement with Avion for Lupuzor

UK-based pharmaceutical company ImmuPharma has signed a licensing and development agreement with US-based Avion Pharmaceuticals for Lupuzor, a peptide therapeutic and a first-in-class autophagy immunomodulator for auto-immune disease systemic lupus erythematosus (SLE or lupus). Under the agreement, the two firms...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read